China Medicine Corporation
CHME · OTC
12/31/2009 | 12/31/2008 | 12/31/2007 | 12/31/2006 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.47 | 0.17 | -0.37 | -0.00 |
| FCF Yield | 20.24% | 14.12% | -7.67% | -13.99% |
| EV / EBITDA | 5.62 | 0.72 | 3.20 | 3.37 |
| Quality | ||||
| ROIC | 5.61% | 20.50% | 21.30% | 34.99% |
| Gross Margin | 29.32% | 29.03% | 29.44% | 37.41% |
| Cash Conversion Ratio | 12.10 | 0.46 | -0.34 | -0.46 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.43% | 30.77% | – | 32.13% |
| Free Cash Flow Growth | 761.00% | 157.16% | 11.33% | -9,268.30% |
| Safety | ||||
| Net Debt / EBITDA | 0.68 | -0.25 | -0.63 | -0.06 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 16.76 | 8.06 | 7.52 | 7.90 |
| Cash Conversion Cycle | 137.03 | 179.60 | 165.69 | 148.99 |